NCT03015207View on ClinicalTrials.gov

First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity

PHASE1CompletedINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

January 6, 2017

Primary Completion Date

October 26, 2017

Study Completion Date

October 26, 2017

Conditions

Metabolism and Nutrition DisorderObesity

Interventions

DRUG

NNC0194-0499

DRUG

Placebo

Trial Locations (1)

78209

Novo Nordisk Investigational Site, San Antonio

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY

NCT03015207 - First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity | Biotech Hunter | Biotech Hunter